Stoke Therapeutics, Inc.
STOK
$31.27
-$0.04-0.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 9.33M | 6.23M | 1.40M | 10.63M | 13.82M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.33M | 6.23M | 1.40M | 10.63M | 13.82M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 9.33M | 6.23M | 1.40M | 10.63M | 13.82M |
| SG&A Expenses | 25.25M | 19.97M | 21.15M | 16.03M | 15.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 74.75M | 59.65M | 62.84M | 53.72M | 41.12M |
| Operating Income | -65.43M | -53.42M | -61.44M | -43.09M | -27.30M |
| Income Before Tax | -61.62M | -50.00M | -57.93M | -39.63M | -23.48M |
| Income Tax Expenses | -- | -- | -- | -1.28M | -- |
| Earnings from Continuing Operations | -61.62M | -50.00M | -57.93M | -38.35M | -23.48M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.62M | -50.00M | -57.93M | -38.35M | -23.48M |
| EBIT | -65.43M | -53.42M | -61.44M | -43.09M | -27.30M |
| EBITDA | -64.97M | -52.98M | -61.03M | -42.65M | -26.85M |
| EPS Basic | -0.93 | -0.79 | -0.93 | -0.65 | -0.40 |
| Normalized Basic EPS | -0.58 | -0.50 | -0.58 | -0.42 | -0.25 |
| EPS Diluted | -0.93 | -0.79 | -0.94 | -0.65 | -0.40 |
| Normalized Diluted EPS | -0.58 | -0.50 | -0.58 | -0.42 | -0.25 |
| Average Basic Shares Outstanding | 66.02M | 63.06M | 62.04M | 58.61M | 58.35M |
| Average Diluted Shares Outstanding | 66.02M | 63.06M | 62.04M | 58.61M | 58.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |